Company Performance Metrics
- Atul Dandekar: Co-Founder
- Jason Ehrlich: CEO & Co-Founder
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases. The company creates drug candidates designed to address conditions such as diabetic macular edema, wet age-related macular degeneration, and thyroid eye disease by targeting validated biological pathways. Its pipeline includes therapies such as
OLN324, a VEGF/Ang2 bispecific antibody candidate, and OLN102, an IGF-1R/TSHR bispecific antibody candidate for ophthalmic applications. Ollin Biosciences applies research-driven drug development strategies to create potential treatments that aim to improve disease management and patient outcomes. The company combines scientific research, clinical development, and ophthalmology expertise to advance new medicines for patients affected by severe eye conditions.
